UK-based home healthcare provider Cera has raised $150 million in debt and equity funding to help scale its AI-driven platform. This round was led by funds affiliated with BDT & MSD Partners and Schroders Capital. While the company disclosed that most new funds are in debt, it refrained from detailing the exact split or its current valuation.
The company utilises proprietary data modelling to improve healthcare outcomes, though it also integrates elements from Gemini AI and ChatGPT. By leveraging AI to predict patient risks such as falls or hospitalizations, Cera claims to reduce hospital admissions and expedite patient discharges significantly.
With this funding, Cera aims to integrate technology further into its care model, positioning itself as a critical support system for the National Health Service (NHS).
“We are getting to profitability, plus we have very significant stale how we’re using our technology and AI. We’ve expanded into more services in the home,” said Dr Ben Maruthappu MBE, Founder & CEO of Cera for TechCrunch.
Cera’s carers use an app to manage work schedules and log patient data. This is followed by the processing of unstructured data through AI models to predict health risks, such as falls or hospitalizations. Cera claims to have reduced hospital admissions by up to 70% and patient falls by 20%, speeding up hospital discharges.
In the UK, Cera competes with providers like Home Instead and Bluebird Care, which rely on non-proprietary apps. Similar companies in the US include Signify Health and CVS Health’s home care division. Another competitor, Honor, has raised $625 million to date.
Maruthappu emphasised Cera’s role in alleviating NHS pressures while expanding into comprehensive home healthcare services. By leveraging its extensive data set, Cera’s AI can predict and mitigate health risks, reduce hospitalizations, and enhance patient outcomes.